e overall response rate was 29.3%. No signi cant associations were found among GNAS1 T393C polymorphism and the objective response rate. e disease control rate of patients with GNAS1 T393C CC genotype was lower than that of patients with variant genotype ( or CT) (46.2% vs 73.8%, P=0.039). Univariate analysis identi ed gender, smoking history, histology and GNAS1 T393C polymorphism as predictive marker of PFS (P=0.04, P<0.001, P<0.001 and P=0.005). Multivariate analysis of factors, including smoking history, performance status score, histology, GNAS1 T393C polymorphism demonstrated that GNAS1 T393C polymorphism was correlated independently with PFS (P=0.007). Conclusion Our data suggest the role of GNAS1 T393C CC genotype as a poor predictive marker both of DCR and PFS in advanced NSCLC patients treated with tyrosine kinase inhibitor.
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μL，2*GoldStar Taqman Mixture（with ROX） 12.5 μL，上、
溴化乙锭（0.5 μg/mL）在电压120 V的琼脂糖凝胶电泳体 系电泳60 min。
疗效评价标准 疗效评定采用实体瘤疗效评价标准
（Response Evaluation Criteria in Solid Tumors, RECIST 1.1） [9] ，分为完全缓解（complete response, CR）、部分 缓解（partial response, PR）、稳定（stable disease, SD）和 进展（progressive disease, PD）。客观缓解率（objective www.lungca.org www.lungca.org 
